Literature DB >> 12168086

Role of the orphan nuclear receptor ROR alpha in the control of the metastatic behavior of androgen-independent prostate cancer cells.

Roberta M Moretti1, Marina Montagnani Marelli, Marcella Motta, Patrizia Limonta.   

Abstract

Orphan nuclear receptors constitute a subgroup of the superfamily of steroid/thyroid/retinoid receptors for which no endogenous ligand has been identified. The orphan nuclear receptor ROR alpha has been shown to be involved in the control of cell growth and differentiation. We have previously shown that, in DU 145 androgen-independent prostate cancer cells, ROR alpha activation brings about a significant decrease of cell proliferation and affects cell cycle progression through the modulation of cell cycle-related genes. The experiments here described have been performed to clarify whether ROR alpha might also be involved in the control of the metastatic behavior of DU 145 cells. We have shown that the thiazolidinedione derivative CGP 52608, the specific ROR alpha ligand and activator, reduces the ability of DU 145 cells to invade a reconstituted basement membrane (Matrigel). CGP 52608 also significantly decreased the capacity of prostate cancer cells to migrate towards a chemotactic stimulus (fibronectin), when plated in the upper compartment of a Boyden's chamber. Moreover, ROR alpha activation resulted in a decreased expression of alpha v beta 3 integrin and an increased level of expression of beta 4 integrin subunit. These findings indicate that the activation of the orphan nuclear receptor ROR alpha reduces the invasive and migratory capacities of androgen-independent prostate cancer cells, at least partially, by affecting integrin expression.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12168086

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  9 in total

1.  Genetic variants in RORA and DNMT1 associated with cutaneous melanoma survival.

Authors:  Bo Li; Yanru Wang; Yinghui Xu; Hongliang Liu; Wendy Bloomer; Dakai Zhu; Christopher I Amos; Shenying Fang; Jeffrey E Lee; Xin Li; Jiali Han; Qingyi Wei
Journal:  Int J Cancer       Date:  2018-01-17       Impact factor: 7.396

2.  Epigenetic Regulation in Breast Cancer.

Authors:  Hye Jin Nam; Sung Hee Baek
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

3.  The molecular genetics of autism spectrum disorders: genomic mechanisms, neuroimmunopathology, and clinical implications.

Authors:  Daniel J Guerra
Journal:  Autism Res Treat       Date:  2011-05-17

4.  Association between Prostinogen (KLK15) genetic variants and prostate cancer risk and aggressiveness in Australia and a meta-analysis of GWAS data.

Authors:  Jyotsna Batra; Felicity Lose; Tracy O'Mara; Louise Marquart; Carson Stephens; Kimberly Alexander; Srilakshmi Srinivasan; Rosalind A Eeles; Douglas F Easton; Ali Amin Al Olama; Zsofia Kote-Jarai; Michelle Guy; Kenneth Muir; Artitaya Lophatananon; Aneela A Rahman; David E Neal; Freddie C Hamdy; Jenny L Donovan; Suzanne Chambers; Robert A Gardiner; Joanne Aitken; John Yaxley; Mary-Anne Kedda; Judith A Clements; Amanda B Spurdle
Journal:  PLoS One       Date:  2011-11-23       Impact factor: 3.240

Review 5.  EZH2 in Bladder Cancer, a Promising Therapeutic Target.

Authors:  Mónica Martínez-Fernández; Carolina Rubio; Cristina Segovia; Fernando F López-Calderón; Marta Dueñas; Jesús M Paramio
Journal:  Int J Mol Sci       Date:  2015-11-13       Impact factor: 5.923

Review 6.  The Role of Nuclear Receptors in Prostate Cancer.

Authors:  Masaki Shiota; Naohiro Fujimoto; Eiji Kashiwagi; Masatoshi Eto
Journal:  Cells       Date:  2019-06-17       Impact factor: 6.600

7.  Isoform-Specific Lysine Methylation of RORα2 by SETD7 Is Required for Association of the TIP60 Coactivator Complex in Prostate Cancer Progression.

Authors:  Hyerin Song; Jung Woong Chu; Su Chan Park; Hyuntae Im; Il-Geun Park; Hyunkyung Kim; Ji Min Lee
Journal:  Int J Mol Sci       Date:  2020-02-27       Impact factor: 5.923

Review 8.  Ellagic Acid, Kaempferol, and Quercetin from Acacia nilotica: Promising Combined Drug With Multiple Mechanisms of Action.

Authors:  Mosab Yahya Al-Nour; Musab Mohamed Ibrahim; Tilal Elsaman
Journal:  Curr Pharmacol Rep       Date:  2019-05-14

9.  RORα Suppresses Epithelial-to-Mesenchymal Transition and Invasion in Human Gastric Cancer Cells via the Wnt/β-Catenin Pathway.

Authors:  Jian Su; Bo Su; Hong Xia; Fang Liu; XiaoHong Zhao; Juan Li; JiZhen Zhang; Ying Shi; Ying Zeng; Xi Zeng; Hui Ling; YouHua Wu; Qi Su
Journal:  Front Oncol       Date:  2019-12-06       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.